GIST

Antonescu CR, Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res. 2005;11:4182-4190.External Source Document | Internal Use Of This Reference 

Blanke CD, Corless CL. State-of-the art therapy for gastrointestinal stromal tumors. Cancer Invest. 2005;23:274-280.External Source Document | Internal Use Of This Reference 

Blanke CD, Demetri G, von Mehren M, et al. Long-term follow-up of a phase II randomized trial in advanced gastrointestinal stromal tumor (GIST) patients (pts) treated with imatinib mesylate [abstract]. J Clin Oncol. 2006;24:526s. Abstract 9528.External Source Document | Internal Use Of This Reference 

Blanke CD, Joensuu H, Demetri GD, et al. Outcome of advanced gastrointestinal stromal tumor (GIST) patients treated with imatinib mesylate: four-year follow-up of a phase II randomized trial [abstract]. Presented at: 2006 Gastrointestinal Cancers Symposium; January 26-28, 2006; San Francisco, Calif. Abstract 7.External Source Document | Internal Use Of This Reference 

Blay JY, Bonvalot S, Casali P, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST.External Source Document | Internal Use Of This Reference 

Blay P, Astudillo A, Buesa JM, et al. Protein kinase C theta is highly expressed in gastrointestinal stromal tumors but not in other mesenchymal neoplasias. Clin Cancer Res. 2004;10:4089-4095.External Source Document | Internal Use Of This Reference 

Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001;411:355-365.External Source Document | Internal Use Of This Reference 

Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 2000;295:139-145.External Source Document | Internal Use Of This Reference 

Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 996;56:100-104.External Source Document | Internal Use Of This Reference 

Chen LL, Sabripour M, Andtbacka RH, et al. Imatinib resistance in gastrointestinal stromal tumors. Curr Oncol Rep. 2005;7:293-299.External Source Document | Internal Use Of This Reference 

Chen Y, Tzeng CC, Liou CP, et al. Biological significance of chromosomal imbalance aberrations in gastrointestinal stromal tumors. J Biomed Sci. 2004;11:65-71.External Source Document | Internal Use Of This Reference 

Connolly EM, Gaffney E, Reynolds JV. Gastrointestinal stromal tumours. Br J Surg. 2003;90:1178-1186.External Source Document | Internal Use Of This Reference 

Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol. 2004;22:3813-3825.External Source Document | Internal Use Of This Reference 

D'Amato G, Steinert DM, McAuliffe JC, Trent JC. Update on the biology and therapy of gastrointestinal stromal tumors. Cancer Control. 2005;12:44-56.External Source Document | Internal Use Of This Reference 

d'Auriol L, Mattei MG, Andre C, Galibert F. Localization of the human c-kit protooncogene on the q11-q12 region of chromosome 4. Hum Genet. 1988;78:374-376.External Source Document | Internal Use Of This Reference 

Debiec-Rychter M, Cools J, Dumez H, et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology. 2005;128:270-279.External Source Document | Internal Use Of This Reference 

Debiec-Rychter M, Dumez H, Judson I, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2004;40:689-695.External Source Document | Internal Use Of This Reference 

Debiec-Rychter M, Wasag B, Stul M, et al. Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity. J Pathol. 2004;202:430-438.External Source Document | Internal Use Of This Reference 

Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96:3343-3356.External Source Document | Internal Use Of This Reference 

Dematteo RP, Heinrich MC, El-Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol. 2002;33:466-477.External Source Document | Internal Use Of This Reference 

DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231:51-58.External Source Document | Internal Use Of This Reference 

Demetri G, Benjamin R, Blanke CD, et al. NCCN Task Force report: optimal management of patients with gastrointestinal stromal tumor (GIST)—expansion and update of NCCN Clinical Practice Guidelines. J Natl Compr Canc Netw. 2004;2(suppl 1):S1-S26.External Source Document | Internal Use Of This Reference 

Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-480.External Source Document | Internal Use Of This Reference 

Desai J, Shankar S, Heinrich MC, et al. Clonal evolution of resistance to imatinib (IM) in patients (pts) with gastrointestinal stromal tumor (GIST): molecular and radiologic evaluation of new lesions [abstract]. Proc Am Soc Clin Oncol. 2004;23:197. Abstract 3010.External Source Document | Internal Use Of This Reference 

Dewar AL, Cambareri AC, Zannettino AC, et al. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood. 2005;105:3127-3132.External Source Document | Internal Use Of This Reference 

Duensing A, Joseph NE, Medeiros F, et al. Protein kinase C theta (PKC theta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs). Cancer Res. 2004;64:5127-5131.External Source Document | Internal Use Of This Reference 

Eisenberg BL, Judson I. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol. 2004;11:464-475.External Source Document | Internal Use Of This Reference 

El-Rifai W, Sarlomo-Rikala M, Andersson LC, Knuutila S, Miettinen M. DNA sequence copy number changes in gastrointestinal stromal tumors: tumor progression and prognostic significance. Cancer Res. 2000;60:3899-3903.External Source Document | Internal Use Of This Reference 

Emory TS, Sobin LH, Lukes L, Lee DH, O'Leary TJ. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol. 1999;23:82-87.External Source Document | Internal Use Of This Reference 

Fletcher CDM, Berman JJ, Gorstein F, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33:459-465.External Source Document | Internal Use Of This Reference 

Frost MJ, Ferrao PT, Hughes TP, Ashman LK. Juxtamembrane mutant V560G Kit is more sensitive to imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther. 2002;1:1115-1124.External Source Document | Internal Use Of This Reference 

Ghanem N, Altehoefer C, Furtwangler A, et al. Computed tomography in gastrointestinal stromal tumors. Eur Radiol. 2003;13:1669-1678.External Source Document |Internal Use Of This Reference 

Glivec summary of product characteristics [SMPC]. Basel, Switzerland: Novartis Pharma AG; 2006.External Source Document  | Internal Use Of This Reference 

Goettsch WG, Bos SD, Breekveldt-Postma N, Casparie M, Herings RM, Hogendoorn PC. Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer. 2005;41:2868-2872.External Source Document  | Internal Use Of This Reference 

Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs. 1992;10:239-253.External Source Document  | Internal Use Of This Reference 

Gronchi A, Fiore M, Bertulli R, et al. Surgery of residual disease following imatinib mesylate in advanced gastrointestinal stromal tumors (GIST) [abstract]. J Clin Oncol. 2005;23:825s. Abstract 9038.External Source Document  | Internal Use Of This Reference 

Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive.External Source Document  | Internal Use Of This Reference 

Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21:4342-4349.External Source Document  | Internal Use Of This Reference 

Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299:708-710.External Source Document  | Internal Use Of This Reference 

Heinrich MC, Rubin BP, Longley BJ, Fletcher JA. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol. 2002;33:484-495.External Source Document  | Internal Use Of This Reference 

Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal.External Source Document  | Internal Use Of This Reference 

Hubbard S, Till J. Protein tyrosine kinase structure and function. Annu Rev Biochem. 2000;69:373-398.External Source Document  | Internal Use Of This Reference 

Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G. Management of malignant gastrointestinal stromal tumours. Lancet Oncol. 2002;3:655-664.External Source Document  | Internal Use Of This Reference 

Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344:1052-1056.External Source Document  | Internal Use Of This Reference 

Joensuu H. Current perspectives on the epidemiology of gastrointestinal stromal tumours. Eur J Cancer. 2006;4(suppl 1):4-9.External Source Document  | Internal Use Of This Reference 

Joensuu H. Gastrointestinal stromal tumor (GIST). Ann Oncol. 2006;17(suppl 10):x280-x286.External Source Document  | Internal Use Of This Reference 

Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998;152:1259-1269.External Source Document  | Internal Use Of This Reference 

Kindblom LG. Gastrointestinal stromal tumors: diagnosis, epidemiology, prognosis.External Source Document  | Internal Use Of This Reference 

Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005;353:172-187.External Source Document  | Internal Use Of This Reference 

Miettinen M, El-Rifai W, L HLS, Lasota J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol. 2002;33:478-483.External Source Document  | Internal Use Of This Reference 

Miettinen M, Lasota J. Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics. Pol J Pathol. 2003;54:3-24.External Source Document  | Internal Use Of This Reference 

Miettinen M, Lasota J. Gastrointestinal stromal tumors—definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 2001;438:1-12.External Source Document  | Internal Use Of This Reference 

Miettinen M, Makhlouf H, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol. 2006;30:477-489.External Source Document  | Internal Use Of This Reference 

Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol. 2005;29:52-68.External Source Document  | Internal Use Of This Reference 

Miettinen M, Sobin LH, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Mod Pathol. 2000;13:1134-1142.External Source Document  | Internal Use Of This Reference 

Motegi A, Sakurai S, Nakayama H, et al. PKC theta, a novel immunohistochemical marker for gastrointestinal stromal tumors (GIST), especially useful for identifying KIT-negative tumors. Pathol Int. 2005;55:106-112.External Source Document  | Internal Use Of This Reference 

Nilsson B, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era. Cancer. 2005;103:821-829.External Source Document  | Internal Use Of This Reference 

O'Brien SG, Meinhardt P, Bond E, et al. Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. Br J Cancer. 2003;89:1855-1859.External Source Document  | Internal Use Of This Reference 

Okuda K, Weisberg E, Gilliland DG, Griffin JD. ARG tyrosine kinase activity is inhibited by STI571. Blood. 2001;97:2440-2448.External Source Document  | Internal Use Of This Reference 

Pauwels P, Debiec-Rychter M, Stul M, De Wever I, Van Oosterom AT, Sciot R. Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall. Histopathology. 2005;47:41-47.External Source Document  | Internal Use Of This Reference 

Prasad SR, Jhaveri KS, Saini S, et al. CT tumor measurement for therapeutic response assessment: comparison of unidimensional, bidimensional, and volumetric techniques initial observations. Radiology. 2002;225:416-419.External Source Document  | Internal Use Of This Reference 

Reichardt P. Optimising therapy for GIST patients. Eur J Cancer. 2006;4(suppl 1):19-26.External Source Document  | Internal Use Of This Reference 

Rubin BP. Gastrointestinal stromal tumours: an update. Histopathology. 2006;48:83-96.External Source Document  | Internal Use Of This Reference 

Rutkowski P, Nowecki Z, Nyckowski P, et al. Surgical treatment for patients (pts) with gastrointestinal stromal tumors (GIST) after imatinib mesylate (IM) therapy [abstract]. J Clin Oncol. 2005;23:825s Abstract 9037.External Source Document  | Internal Use Of This Reference 

Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol. 1998;11:728-734.External Source Document  | Internal Use Of This Reference 

Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000;103:211-225.External Source Document  | Internal Use Of This Reference 

Shankar S, vanSonnenberg E, Desai J, et al. Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. Radiology. 2005;235:892-898.External Source Document  | Internal Use Of This Reference 

Tamborini E, Bonadiman L, Greco A, et al. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology. 2004;127:294-299.External Source Document  | Internal Use Of This Reference 

Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.External Source Document  | Internal Use Of This Reference 

Thomsen L, Robinson TL, Lee JC, et al. Interstitial cells of Cajal generate a rhythmic pacemaker current. Nat Med. 1998;4:848-851.External Source Document  | Internal Use Of This Reference 

Torihashi S, Horisawa M, Watanabe Y. c-Kit immunoreactive interstitial cells in the human gastrointestinal tract. J Auton Nerv Syst. 1999;75:38-50.External Source Document  | Internal Use Of This Reference 

Tuveson DA, Willis NA, Jacks T, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene. 2001;20:5054-5058.External Source Document  | Internal Use Of This Reference 

Van Den Abbeele AD, Badawi RD, Manola J, et al. Effects of cessation of imatinib mesylate (IM) therapy in patients (pts) with IM-refractory gastrointestinal stromal tumors (GIST) as visualized by FDG-PET scanning [abstract]. Proc Am Soc Clin Oncol. 2004;23:198. Abstract 3012.External Source Document  | Internal Use Of This Reference 

Van Oosterom AT, Dumez H, Desai J, et al. Combination signal transduction inhibition: a phase I/II trial of the oral mTOR-inhibitor everolimus (E, RAD001) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM [abstract]. Proc Am Soc Clin Oncol. 2004;23:195. Abstract 3002.External Source Document  | Internal Use Of This Reference 

Wakai T, Kanda T, Hirota S, et al. Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation. Br J Cancer. 2004;90:2059-2061.External Source Document  | Internal Use Of This Reference 

Yamaguchi M, Matsumoto T, Tate G, Higuchi T. Secondary resistance to imatinib mesylate in a patient with unresectable duodenal GIST without mutations in exons 9, 11, 13, or 17 of the c-kit protooncogene. J Gastroenterol. 2004;39:904-905.External Source Document  | Internal Use Of This Reference 

Hepatitis

A. Takeda, J. Jones, J. Shepherd, P. Davidson and A. Price. A systematic review and economic evaluation of adefovir dipivoxil and pegylated interferon-alpha-2a for the treatment of chronic hepatitis B. Journal of Viral Hepatitis 2007 Feb;14(2):75-88.External Source Document  | Internal Use Of This Reference 

Barouki FM, Witter FR, Griffin DE, et al. Time course of interferon levels, antiviral state, 2',5'- oligoadenylate synthetase and side effects in healthy men. J Interferon Res 1987;7(1):29–39.External Source Document  | Internal Use Of This Reference 

Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988;61(10):1942–56.External Source Document  | Internal Use Of This Reference 

Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001;32(3):492-7.External Source Document  | Internal Use Of This Reference 

Bonino F, Brunetto B. Chronic hepatitis B e antigen (HBeAg) negative, anti-HBe positive hepatitis B: an overview. J Hepatol 2003;39 (Suppl 1):S160–S3.External Source Document  | Internal Use Of This Reference 

Brunetto M et al. On-treatment HBsAg decline in HBeAg-negative patients as a predictor of response to peginterferon alfa-2a (40KD) therapy 3 years off-treatment: potential for response-guided therapy. J Hepatol 2008;48(Suppl 2):S254.External Source Document  | Internal Use Of This Reference 

Brunetto MR, Oliveri F, Coco B, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002;36(2):263–70.External Source Document  | Internal Use Of This Reference 

Buster EH, Flink HJ, Cakaloglu Y et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg positive patients treated with peginterferon alpha-2B. Hepatology 2007;46(4 Suppl 1):965 (Abstract).External Source Document  | Internal Use Of This Reference 

Carman WF, Jacyna MR, Hadziyannis S, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989;2(8663):588-91.External Source Document  | Internal Use Of This Reference 

Chan HL-Y. A Randomized, Controlled Trial of Combination Therapy for Chronic Hepatitis B: Comparing Pegylated Interferon-alfa2b and Lamivudine with Lamivudine Alone. Ann Intern Med2005;142:240–50.External Source Document  | Internal Use Of This Reference 

Chu CJ, Keeffe EB, Han SH, et al. Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology 2003;125(2):444–51.External Source Document  | Internal Use Of This Reference 

Conry-Cantilena C. et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med. 1996;334(26):1691-6.External Source Document  | Internal Use Of This Reference 

Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003;10(4):298–305.External Source Document  | Internal Use Of This Reference 

de Franchis R, Hadengue A, Lau G, et al. EASL International Consensus Conference on Hepatitis B. 13–14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol 2003;39 (Suppl 1) :S3–25.External Source Document  | Internal Use Of This Reference 

Dejean A, Sonigo P, Wain-Hobson S, Tiollais P. Specific hepatitis B virus integration in hepatocellular carcinoma DNA through a viral 11-base-pair direct repeat. Proc Natl Acad Sci USA 1984;81(17):5350–4.External Source Document  | Internal Use Of This Reference 

Fattovich G, Rugge M, Brollo L, et al. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology 1986;6(2):167–72.External Source Document  | Internal Use Of This Reference 

Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis 2003;23(1):47-58.External Source Document  | Internal Use Of This Reference 

Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998;27(1):209-12.External Source Document  | Internal Use Of This Reference 

Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirn for chronic hepatitis C virus infection. N Engl J Med 2002; 347(13):975-82.External Source Document  | Internal Use Of This Reference 

Funk ML, Rosenberg DM, Lok ASF. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated pre-core and core promoter variants. J Viral Hepat 2002;9(1):52-61.External Source Document  | Internal Use Of This Reference 

Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996;334(13):815-20.External Source Document  | Internal Use Of This Reference 

Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999;6(1):35-47.External Source Document  | Internal Use Of This Reference 

Gust ID. Epidemiology of hepatitis B infection in the Western Pacific and South East Asia. Gut 1996;38(Suppl 2):S18–23.External Source Document  | Internal Use Of This Reference 

Hadziyannis S, Lau GKK, Marcellin P, et al. Sustained HBsAg seroconversion in patients with chronic hepatitis B treated with peginterferon alfa-2a (40KD) (PEGASYS®). J Hepatol 2005;42(2):178 (Abstract).External Source Document  | Internal Use Of This Reference 

Hadziyannis SJ, Sette H, Jr., Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140(5):346-55.External Source Document  | Internal Use Of This Reference 

Hagan H, Latka MH, Campbell JV, et al. Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities. Clin Infect Dis 2006;42(5):669-72.External Source Document  | Internal Use Of This Reference 

Hoofnagle JH, Dusheiko GM, Seeff LB, Jones EA, Waggoner JG, Bales ZB. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med 1981;94(6):744–8.External Source Document  | Internal Use Of This Reference 

Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997;26 (3 Suppl 1):15S-20S.External Source Document  | Internal Use Of This Reference 

Kao JH, Chen PJ, Lai MY, Chen DS. Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection. J Clin Microbiol 2002;40(4):1207-9.External Source Document  | Internal Use Of This Reference 

Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol 2004;2(2):87-106.External Source Document  | Internal Use Of This Reference 

Kim WR, Benson JT, Therneau TM, Torgerson HA, Yawn BP, Melton LJ, 3rd. Changing epidemiology of hepatitis B in a U.S. community. Hepatology 2004;39(3):811–6.External Source Document  | Internal Use Of This Reference 

Lau GKK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352(26):2682–95.External Source Document  | Internal Use Of This Reference 

Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat.External Source Document  | Internal Use Of This Reference 

Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver International 2005;25:472–89.External Source Document  | Internal Use Of This Reference 

Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 – summary of a workshop. Gastroenterology 2001;120(7):1828–53.External Source Document  | Internal Use Of This Reference 

Maddrey WC. Hepatitis B: an important public health issue. J Med Virol 2000;61(3):362–6.External Source Document  | Internal Use Of This Reference 

Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358(9286):958-65.External Source Document  | Internal Use Of This Reference 

Marcellin P et al. Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a. Liver Int 2008;28(4):477–85.External Source Document  | Internal Use Of This Reference 

Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351(12):1206–17.External Source Document  | Internal Use Of This Reference 

Mathei C, Buntinx F, van Damme P. Seroprevalence of hepatitis C markers among intravenous drug users in western European countries: a systematic review. J Viral Hepat 2002;9(3):157-73.External Source Document  | Internal Use Of This Reference 

Mayo MJ. Extrapepatic manifestations of hepatitis C infection. Am J Med Sci 2003;325(3):135-48.External Source Document  |

Atopic Dermatitis

• Prevalence of Atopic Dermatitis
• Management of Atopic Dermatitis
• Treatment Options for Atopic Dermatitis
• Atopic Dermatitis Resources

CONNECT

• EPG Mobile
• Congress Diary

DISEASE CENTRES

• Post-MI Heart Failure
• Prostate Cancer
• Renal Cell Carcinoma
• Multiple Sclerosis
• Men's Health

  CongresseshomeMen's healthDefinitionPrevalenceSymptomsClinical examinationLaboratory testingPatient based Physical examinationSpecialized diagnostic testsHow erection worksProblems with erectionLifestyleMedicationMetabolic SyndromeOverviewProstatectomyTestosterone Deficiency and HypogonadismAlgorithmFirst- line therapySecond-line therapyThird-line therapyDurationED & DiabetesED & DyslipidemiaED & HypertensionED & metabolic syndromeED & Radical ProstatectomyED & The Role of Female PartnerFast onsetFirst dose SuccessHardnessMode of ActionPERTPharmacokineticsPharmacologyReceptor AffinityReliabilitySafety & TolerabilityDiagnosis - Diagnosis and Treatment AlgorithmDiagnosis - Symptoms, Physical Examination, Blood TestsEtiology - Etiology Of HypogonadismEtiology - Late Onset HypogonadismEtiology - Primary and Secondary HyponadismEtiology - Risk Factors For HypogonadismOverview - Current treatment and controversiesOverview - How are men affected by hypogonadism?Overview - How important is it to treat hypogonadismOverview - Hypogonadism DefinedOverview - Hypogonadism PrevalenceDiagnosis - Symptoms, Physical Examination, Blood TestsTreatment Options - Safety Of Testosterone Replacement TherapyTreatment Options - What Are The Benefits Of Treating Hypogonadism?Treatment Options - What Treatments Are Available?Treatment OptionsLatest UpdatesTestogel reduces fat and improves bodyTestosterone improves functional performanceTestosterone reduces visceral fatAssociations & OrganisationsFurther Reading - Erectile DysfunctionFurther Reading - Hypogonadism

• Atopic Dermatitis
• Neuropathic Pain
• Soft Tissue Sarcoma
• Niemann-Pick Type C
• Cystic Fibrosis
• Cholesterol
• Contraception
• Hepatitis
• Renal Anaemia
• CML
• GIST
• Parkinsons
• Insomnia
• Asthma
• LSD’s
• NSCLC
• Alzheimer's
• Diabetes
• Opioids and Pain
• Arthritis
• Hypertension
• Migraine
• Cervical Cancer
• Ophthalmics

AFFILIATE PARTNERS

• Thrombosis
• Hereditary Angioedema

QUICK SEARCH

• ADHD
• Alzheimers
• Anxiety Disorders
• Arthritis
• Asthma
• Avonex
• Beta-feron
• Breast Cancer
• Cervical Cancer
• Cholesterol
• Colorectal Cancer
• Copaxone
• Depression
• Diabetes
• Erectile Dysfunction
• Extavia
• Hypertension
• Insomnia
• Men's Health
• Meningitis
• Migraine
• Pain Management
• Parkinson's
• Pharma News
• Post-MI
• Pregnancy
• Rebif
• Renal anaemia
• Renal Cell Carcinoma
• Thrombosis
• Thromboembolism
• Tysabri

GUIDELINES

• Chronic Fatigue
• Dental
• Ear Infection
• Eczema
• Hospital Related Illness
• Incontinence
• Infection
• Influenza
• Migraine
• Post-traumatic stress disorder (PTSD)
• Postnatal health
• Rhinitis

DRUG DATA

• Deutsch    
• English
• Español
• Norsk
• Nederlands
• Svenska
• Français
• Português
• Italiano

REFERENCES

• ADHD to Diabetes    
• GIST to HPV
• Hypertension to Migraine
• Niemann-Pick to Parkinsons
• Renal Anaemia to Thrombosis